Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DCMG03
|
|||
| Drug Name |
TTX-030
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-10: C81-C86; ICD-9: 202] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | ||
| Company |
AbbVie
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) | Target Info | Inhibitor | [2] |
| BioCyc | UTP and CTP dephosphorylation II | |||
| KEGG Pathway | Purine metabolism | |||
| Pyrimidine metabolism | ||||
| Epstein-Barr virus infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03884556) TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of AbbVie. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.